Background and purpose:Perioperative hypothermia will affect the prognosis of cancer patients. Amino acid infusion can increase the core temperature by endogenous thermogenesis. And the forced-air warming system has gained high acceptance as a measure for rewarming. This study aimed to find out whether amino acid infusion was effective to treat postoperative hypothermia and how well the treatment effect was when compared with the forced-air warming system.Methods:Fifty-seven ASAⅠ orⅡ patients aged 18-60 years undergoing elective esophageal or gastric cancer operation under epidural-general anesthesia and whose core temperature were below 36℃. When admitted to the recovery room wererandomly divided into 3 groups (n=19): GroupⅠ received intravenous infusion of mixed amino acid at a rate of 2 mL·kg-1·h-1 (A); GroupⅡ received a forced-air system (B); groupⅢreceived no therapy (C). Rectal temperature and thermal comfort were recorded per 5 min during the ifrst 1 h and oral temperature and thermal comfort were recorded at the 2, 6 and 24 h. ABG was recorded when patients were admitted to the recovery room and at the ifrst hour.Results:At the ifrst hour, the rectal temperature and thermal comfort of groups A and B were higher when compared with group C (P<0.05), and there was no difference between groups A and B (P>0.05). At the second and sixthhour, the temperature and thermal comfort of group A were higher when compared with group B and C (P<0.05), and there was no difference between groups B and C (P>0.05). At the 24th hour, there were no statistically signiifcant differences in the temperature and thermal comfort among the three groups (P>0.05).
Conclusion:The rewarming effect of infusion of mixed amino acid is better than that of the forced-air warming system. It is the more effective and convenient method to rewarm the postoperative hypothermia.

Objective:To explore the blood loss during liposuction for secondary lymphedema of the lower extremities and to analyze the risk factors that influence the blood loss.Methods:Retrospective analysis of the clinical data of patients with secondary lymphedema of lower extremities at the Department of Lymphatic Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital from January 2019 to December 2019. The following clinical indicators were correlated with the amount of blood loss, including age, body mass, body mass index (BMI), primary disease, hypertension, radiotherapy history, chemotherapy history, erysipelas history, affected extremity, duration of swelling, duration of primary disease, International Society of Lymphology(ISL) stage, time of operation, infiltration volume, fat aspiration, blood-tinged fluid solution, volume difference, preoperative hemoglobin. Pearson analysis was used for the univariate analysis of continuous variables, Spearman analysis was used for the univariate analysis of classified variables, multiple linear regression was used for multivariate analysis of continuous variables, and Logistic regression was used for the multivariate analysis of classified variables.Results:174 patients were enrolled, all females with a median age of 55 years. Univariate analysis showed that the age( r=0.17, P=0.026), the body mass( r=0.37, P<0.001), BMI( r=0.29, P<0.001), hypertension( r=0.25, P=0.001), the ISL stage( r=0.40, P<0.001), operative time( r=0.44, P<0.001), infiltration volume( r=0.53, P<0.001), fat aspiration( r=0.36, P<0.001), blood-tinged fluid solution( r=0.61, P<0.001) and volume difference( r=0.63, P<0.001) were associated with the blood loss. There was no correlation between primary disease, radiotherapy history, chemotherapy history, erysipelas history, affected extremity, duration of swelling, duration of primary disease, preoperative hemoglobin and blood loss( P>0.05). Multivariate analysis showed that hypertension ( r=0.14, P=0.012), operative time ( r=0.15, P=0.019) and volume difference ( r=0.30, P=0.001) were independent risk factors affecting blood loss. Conclusion:Hypertension, operative time and volume difference are the risk factors of blood loss during liposuction for secondary lymphedema of the lower extremities.

Objective:To explore the blood loss during liposuction for secondary lymphedema of the lower extremities and to analyze the risk factors that influence the blood loss.Methods:Retrospective analysis of the clinical data of patients with secondary lymphedema of lower extremities at the Department of Lymphatic Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital from January 2019 to December 2019. The following clinical indicators were correlated with the amount of blood loss, including age, body mass, body mass index (BMI), primary disease, hypertension, radiotherapy history, chemotherapy history, erysipelas history, affected extremity, duration of swelling, duration of primary disease, International Society of Lymphology(ISL) stage, time of operation, infiltration volume, fat aspiration, blood-tinged fluid solution, volume difference, preoperative hemoglobin. Pearson analysis was used for the univariate analysis of continuous variables, Spearman analysis was used for the univariate analysis of classified variables, multiple linear regression was used for multivariate analysis of continuous variables, and Logistic regression was used for the multivariate analysis of classified variables.Results:174 patients were enrolled, all females with a median age of 55 years. Univariate analysis showed that the age( r=0.17, P=0.026), the body mass( r=0.37, P<0.001), BMI( r=0.29, P<0.001), hypertension( r=0.25, P=0.001), the ISL stage( r=0.40, P<0.001), operative time( r=0.44, P<0.001), infiltration volume( r=0.53, P<0.001), fat aspiration( r=0.36, P<0.001), blood-tinged fluid solution( r=0.61, P<0.001) and volume difference( r=0.63, P<0.001) were associated with the blood loss. There was no correlation between primary disease, radiotherapy history, chemotherapy history, erysipelas history, affected extremity, duration of swelling, duration of primary disease, preoperative hemoglobin and blood loss( P>0.05). Multivariate analysis showed that hypertension ( r=0.14, P=0.012), operative time ( r=0.15, P=0.019) and volume difference ( r=0.30, P=0.001) were independent risk factors affecting blood loss. Conclusion:Hypertension, operative time and volume difference are the risk factors of blood loss during liposuction for secondary lymphedema of the lower extremities.

Objective:To handle blood loss during liposuction for secondary lymphedema of lower extremities in patients with secondary lymphedema.Methods:The clinical data of 214 patients with secondary lymphedema of the lower extremities undergoing liposuction at Department of Lymphatic Surgery, Capital Medical University Affliated Beijing Shijitan Hospital from Sep 2018 to Jan 2020 were retrospectively analyzed.Results:There were 209 females and 5 males. The average fat aspiration was (2 934.58±1 114.83) ml, the average blood loss was (986.04±425.16) ml, 117 patients were transfused, including autologous transfusion in 90 patients, 15 patients received allogeneic blood, and 12 patients received autologous plus allogeneic blood. The disease phase, operative time and fat aspiration were positively correlated with blood loss, and were independent risk factors affecting blood loss.Conclusion:Liposuction for secondary lymphedema of the lower extremity is an important factor leading to anemia.

Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Humans ; Lymphoma, Follicular ; drug therapy ; Rituximab

Objective: To investigate the efficacy and safety of IA regimen which contains idarubicin (IDA) 8 mg/m², 10 mg/m² or 12 mg/m² as induction chemotherapy for adult patients with de-novo acute myeloid leukemia (AML) . Methods: A total of 1 215 newly diagnosed adult AML patients, ranging from May 2011 to March 2015 in the First Affiliated Hospital of Soochow University and other 36 clinical blood centers in China were enrolled in the multicenter, single-blind, non-randomized, clinical controlled study. To compare the response rate of complete remission (CR) , adverse events between different dose idarubicin combined with cytarabine (100 mg/m²) as induction chemotherapy in newly diagnosed patients of adult AML. Results: Of 1 207 evaluable AML patients were assigned to this analysis of CR rate. The CR rates of IDA 8 mg/m² group, IDA 10 mg/m² group and IDA 12 mg/m² group were 73.6% (215/292) , 84.1% (662/787) and 86.7% (111/128) , respectively (P<0.001) . After adjusted for age, blast ratio of bone marrow, FAB classification and risk stratification, the odds ratios (95% CI) of IDA 10 mg/m² group and IDA 12 mg/m² group were 0.49 (0.34-0.70) and 0.36 (0.18-0.71) , as compared with the IDA 8 mg/m² group (P<0.001, P=0.003) . In the intermediate and favorable groups, CR rates was 76.5% (163/213) , 86.9% (506/582) and 86.1% (68/79) in different doses of IDA (P=0.007) . Interestingly, IA regimen with IDA 10 mg/m² was the only beneficial factor affecting CR in this group after adjusted for age, blast ratio of bone marrow and FAB classification[OR=0.47 (95% CI 0.31-0.71) , P<0.001]. CR rates in adverse group was 50.0% (18/36) , 60.6% (43/71) and 81.8% (18/22) respectively (P=0.089) . However, the odds ratios (95% CI) of IDA 12 mg/m² when compared with the IDA 8 mg/m² was 0.22 (0.06-0.80) , after adjusted for age, blast ratio of bone marrow and FAB classification. The median time (days) of neutrophil count less than 0.5×10⁹/L in IDA 8 mg/m² group, IDA 10 mg/m² group and IDA 12 mg/m² group were 14 (11-18) , 15 (11-20) and 18 (14-22) , respectively (P=0.012) and of platelet count lower than 20×10⁹/L were 14 (7-17) , 15 (11-20) and 17 (15-21) , respectively (P=0.001) . The incidences of lung infection in the three groups were 9.8%, 13.5% and 25.2%, respectively (P<0.001) . Conclusions For young adult patients (aged 18-60 years) with AML in China, intensifying induction therapy with idarubicin 10 mg/m² is clinically superior to IDA 8 mg/m² and IDA 12 mg/m² in favorable intermediate AML subgroup. However, idarubicin 12 mg/m² is more suitable to adverse AML subgroup.

OBJECTIVEA prospective, multicenter and non-interventional prospective study was conducted to evaluate the clinical features of rituximab combined with chemotherapy (R-Chemo) as first-line treatment on newly diagnosed Chinese patients with diffuse large B-cell lymphoma (DLBCL).

METHODSThis was a single arm, prospective, observational multicenter and phase IV clinical trial for 279 patients, who were newly diagnosed as CD20-positive DLBCL from 24 medical centers in China 2011 and 2012, no special exclusion criteria were used. All patients received rituximab based R-Chemo regimes, such as R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone) and other regimes as the first-line treatment. The treatment strategies were determined by physicians and patients without detailed description for treatment course, dose, interval time and examination. Clinical response and safety of all patients were investigated in 120 days after completion of last dose of rituximab.

RESULTSOf 279 patients, 258 with stage I-IV who received at least 1 cycle of rituximab treatment and completed at least one time of tumor assessment were enrolled into intention-to-treat analysis, including 148 male and 110 female. The median age of all patients was 57.2(12.8-88.4) years. ECOG performance statuses of 0 or 1 were observed in 91.1% of patients, international prognostic index levels in the low-risk and low-middle-risk groups in 76.4% of patients, the tumor diameters smaller than 7.5 cm in 69.0% of patients. All patients received 6 median cycles of R-Chemo treatment every 24.4 days. R-CHOP treatment was shown to improve the clinical response with overall response rates of 94.2%. Common adverse events included anemia, marrow failure, leukopenia, thrombocytopenia, digestive diseases, infection and liver toxicity. All adverse events are manageable.

CONCLUSIONNon-interventional clinical trial of R-Chemo remains the standard first-line treatment for newly diagnosed patients with DLBCL in real clinical practice, which is consistent with international treatment recommendations for DLBCL patients. R-Chemo can provide the clinical evidence and benefit as the first-line standard treatment for Chinese patients with DLBCL.

Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Child ; Female ; Humans ; Lymphoma, Large B-Cell, Diffuse ; drug therapy ; Male ; Middle Aged ; Prospective Studies ; Rituximab ; Treatment Outcome